Focus: U.S. Stocks Q4 2025 Earnings Reports Pfizer announced its fourth-quarter results on Tuesday, with profits exceeding Wall Street's expectations. The performance growth was driven by sustained strong demand for classic medications such as apixaban and Vyndaqel.
According to data compiled by the London Stock Exchange Group, on an adjusted basis, Pfizer's fourth-quarter earnings per share were 66 cents, surpassing the analyst consensus estimate of 57 cents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.